Asceneuron asceneuron.com


Public lists: Pharma Startups (4734)

Asceneuron researches and develops oral small molecule therapeutics targeting tauopathies for treating progressive supranuclear palsy (PSP), other related neurodegenerative diseases and Alzheimer's disease. The lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, has entered the critical regulatory studies to allow its entry into human clinical testing. Neuronal deposits of the microtubule-associated tau protein are a common feature ...Show all

Asceneuron researches and develops oral small molecule therapeutics targeting tauopathies for treating progressive supranuclear palsy (PSP), other related neurodegenerative diseases and Alzheimer's disease. The lead product, an O-GlcNAcase inhibitor ...Show all

Company (Alive / Active)

Phone:

Fax:

EPFL Innovation Park
Batiment B
Lausanne, CH-1015
Switzerland

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Asceneuron $37.5M Oct 6, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Asceneuron Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 6 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Glycosidase inhibitors Aug 27, 2015 Application